BIOATLA, INC. Debt Instrument, Fair Value Disclosure
BIOATLA, INC. (BCAB) had Debt Instrument, Fair Value Disclosure of $4.10 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes
us-gaap:DebtInstrumentFairValue · last filed 2026-03-31
- 2025-12-31: Debt Instrument, Fair Value Disclosure $4.10M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2025-12-31 | $4.10M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |